People: Catalyst Biosciences Inc (CBIO.OQ)
Dr. Stephen Anthony Hill, M.D. Director of the company., He was the president and chief executive officer of Targacept since December 2012. From May 2012 to November 2012, Dr. Hill served as president and chief executive officer of QUE Oncology, a start-up biotechnology company, and, from March 2011 to December 2011, he served as president and chief executive officer of 21st Century Biodefense, Inc., a biodefense company. From April 2008 until its acquisition in December 2010, he served as president and chief executive officer of Solvay Pharmaceuticals, Inc., a pharmaceutical company. Prior to Solvay, he was the president, chief executive officer and director of ArQule, Inc., a pharmaceutical company, from April 1999 to March 2008. Dr. Hill has extensive experience across a range of senior management positions with both pharmaceutical and biotechnology companies. Prior to Solvay and ArQule, Dr. Hill held several leadership positions with F. Hoffmann-La Roche Ltd., including Global Head of Clinical Development, and served for seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery. Dr. Hill was a member of the board of directors of Targacept since December 2012 and became a member of the board of directors of Catalyst in August 2015. He is also a member of the board of directors of Cellectar Biosciences, Inc. (formerly Novelos Therapeutics, Inc.) and Lipocine, Inc. Dr. Hill is a Fellow of the Royal College of Surgeons of England and holds degrees in medicine and surgery from St. Catherine’s College at Oxford University.
|Total Annual Compensation, USD||644,532|
|Restricted Stock Award, USD||339,500|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||693,275|
|Fiscal Year Total, USD||1,677,310|